A familiar trope employed at the climax of movie thrillers is the zombie who returns from the dead to devour the brains of the living.
The biopharmaceutical industry may feel as if it is living in its very own horror show as zombies take the form of retooled, failed policies that are resurrected by presidential candidates and office holders who clamor for price controls thinly disguised as liberalized drug importation laws, statutory price ceilings under Medicare, or price discounts and rebates set by formula or by an unaccountable government bureaucrat. For example, legislation has been introduced in the Massachusetts state senate that would require extensive disclosure of a manufacturer’s research, production and marketing expenses, and empower the state’s Health Policy Commission to set a cap on prices for certain high cost drugs.
Hey, check out all the research scientist jobs. Post your resume today!
